CAS 603139-19-1: Odanacatib
Description:Odanacatib is a small molecule inhibitor that specifically targets cathepsin K, an enzyme involved in bone resorption. It is primarily investigated for its potential use in treating osteoporosis and other bone-related disorders by reducing bone loss and increasing bone density. Odanacatib is characterized by its selective inhibition of cathepsin K, which plays a crucial role in the breakdown of bone tissue. The compound has a relatively long half-life, allowing for less frequent dosing compared to other osteoporosis treatments. Its mechanism of action involves the inhibition of osteoclast activity, which are the cells responsible for bone resorption. Odanacatib has undergone various clinical trials to assess its efficacy and safety profile, showing promise in improving bone mineral density in postmenopausal women. However, its development has faced scrutiny regarding potential cardiovascular risks, leading to a reevaluation of its therapeutic use. Overall, Odanacatib represents a novel approach in the management of osteoporosis, focusing on the inhibition of specific pathways involved in bone metabolism.
Formula:C25H27F4N3O3S
InChI:InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1
InChI key:InChIKey=FWIVDMJALNEADT-SFTDATJTSA-N
SMILES:N#CC1(NC(=O)C(NC(C2=CC=C(C=C2)C=3C=CC(=CC3)S(=O)(=O)C)C(F)(F)F)CC(F)(C)C)CC1
- Synonyms:
- (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]pentanamide
- N<sup>1</sup>-[(1-Cyanocyclopropyl)-4-fluoro-N<sup>2</sup>-[(1S)-2,2,2-trifluoro-1-[4-methylsulfonyl]-1,1′-biphenyl-4-yl] ethyl]-<span class="text-smallcaps">L</span>-leucinamide
- Odanacatib
- MK 0822
- N1-[(1-Cyanocyclopropyl)-4-fluoro-N2-[(1S)-2,2,2-trifluoro-1-[4-methylsulfonyl]-1,1′-biphenyl-4-yl] ethyl]-L-leucinamide
- Pentanamide, N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)[1,1′-biphenyl]-4-yl]ethyl]amino]-, (2S)-

Odanacatib
Ref: IN-DA0039T3
1mg | 77.00 € | ||
2mg | 130.00 € | ||
5mg | 155.00 € | ||
10mg | 166.00 € | ||
25mg | 309.00 € | ||
50mg | 545.00 € | ||
100mg | To inquire |

Ref: 54-BUP04942
25mg | 414.00 € | ||
50mg | 613.00 € | ||
100mg | 892.00 € |

Odanacatib
Ref: TM-T6035
1mg | 49.00 € | ||
2mg | 70.00 € | ||
5mg | 105.00 € | ||
10mg | 168.00 € | ||
25mg | 273.00 € | ||
50mg | 410.00 € | ||
100mg | 607.00 € | ||
1mL*10mM (DMSO) | 118.00 € |

MK-0822
Controlled ProductRef: TR-M425015
10mg | 251.00 € | ||
50mg | 834.00 € | ||
100mg | 1,355.00 € |

MK 0822
Ref: 3D-FM65088
10mg | 278.00 € | ||
50mg | 769.00 € |